# Montenegro Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Montenegro HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Montenegro (MNE)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $6.5M
- Products: 15
- Buyer markets: 18
- Average CAGR: +3.1%
- Global sector size: $251.1B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $176.8B | $6.4M | $77.4B | +11.2% | 15 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.3B | $2.9K | $6.0B | -11.7% | 5 | +0.0% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $13.6B | $333.5 | $5.2B | +18.0% | 1 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $13.4B | $30.9K | $4.6B | -7.0% | 6 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $5.8B | $317.4 | $4.6B | -10.1% | 1 | +0.0% |
| HS 300290 - Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $6.1B | $3.2K | $3.7B | +9.4% | 5 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $4.2B | $64.7 | $2.6B | -54.3% | 3 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $6.1B | $59.0K | $2.3B | +34.9% | 3 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $3.6B | $31.6K | $1.8B | +31.1% | 3 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $1.5B | $31.5 | $1.0B | +8.8% | 1 | +0.0% |
| HS 340600 - Candles, tapers and the like | $1.0B | $13.0 | $640.9M | -0.5% | 1 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $899.8M | $37.2 | $570.1M | -6.3% | 1 | +0.0% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $769.3M | $2.3 | $505.4M | +92.3% | 1 | +0.0% |
| HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.1B | $16.6 | $501.2M | -35.9% | 1 | +0.0% |
| HS 294190 - Antibiotics: n.e.c. in heading no. 2941 | $1.0B | $0.2 | $431.7M | -65.5% | 1 | +0.0% |

## Best markets

- Switzerland, Liechtenstein (CHE): $27.7B calculated opportunity across 1 products.
- Germany (DEU): $15.6B calculated opportunity across 9 products.
- Netherlands (NLD): $14.4B calculated opportunity across 8 products.
- Slovenia (SVN): $9.7B calculated opportunity across 1 products.
- Italy (ITA): $7.2B calculated opportunity across 5 products.
- Belgium (BEL): $7.0B calculated opportunity across 1 products.
- USA, Puerto Rico and US Virgin Islands (USA): $5.8B calculated opportunity across 5 products.
- United Kingdom (GBR): $5.4B calculated opportunity across 3 products.
- France (FRA): $4.0B calculated opportunity across 2 products.
- Ireland (IRL): $3.8B calculated opportunity across 2 products.
- Canada (CAN): $2.2B calculated opportunity across 2 products.
- Poland (POL): $2.1B calculated opportunity across 2 products.

## Growth stars

- HS 330210: +92.3% average CAGR, $505.4M calculated opportunity.
- HS 382499: +34.9% average CAGR, $2.3B calculated opportunity.
- HS 330300: +31.1% average CAGR, $1.8B calculated opportunity.
- HS 300215: +18.0% average CAGR, $5.2B calculated opportunity.
- HS 300490: +11.2% average CAGR, $77.4B calculated opportunity.
- HS 300290: +9.4% average CAGR, $3.7B calculated opportunity.
- HS 300220: +8.8% average CAGR, $1.0B calculated opportunity.
- HS 340600: -0.5% average CAGR, $640.9M calculated opportunity.
- HS 300439: -6.3% average CAGR, $570.1M calculated opportunity.
- HS 330499: -7.0% average CAGR, $4.6B calculated opportunity.

## Diversification opportunities

- HS 300490: 15 buyer markets, $77.4B calculated opportunity.
- HS 330499: 6 buyer markets, $4.6B calculated opportunity.
- HS 382200: 5 buyer markets, $6.0B calculated opportunity.
- HS 300290: 5 buyer markets, $3.7B calculated opportunity.
- HS 340220: 3 buyer markets, $2.6B calculated opportunity.
- HS 382499: 3 buyer markets, $2.3B calculated opportunity.
- HS 330300: 3 buyer markets, $1.8B calculated opportunity.
- HS 300215: 1 buyer markets, $5.2B calculated opportunity.
- HS 293499: 1 buyer markets, $4.6B calculated opportunity.
- HS 300220: 1 buyer markets, $1.0B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.